#1
#1 out of 1
health12h ago
GLP-1 drugs like Ozempic show promise for more than weight loss. But what’s science vs hype?
- Latest findings show GLP-1 drugs may help with heart risk reduction beyond weight loss, in large trials.
- Some GLP-1 drugs may help certain liver conditions, based on small clinical signals.
- Weight loss may indirectly reduce cancer risk, with obesity-linked cancers potentially affected by GLP-1 use.
- Trial data on cancer spread and anti-inflammatory effects remain preliminary and unproven.
- Early signs for endometriosis show promise, yet randomized trials are still lacking.
- Brain effects are complex; some studies show reduced symptoms while others show potential risks.
- There are notable safety concerns, including pancreatitis risk and thyroid cancer signals.
- Most evidence for new uses comes from real-world studies, not large randomized trials.
- Researchers stress cautious interpretation and the need for more rigorous trials before broad adoption.
- The science shows both excitement and hype; clinical guidance remains nuanced.
Vote 0